Global Gout Market

Global Gout Market Size Insights Forecasts to 2035

• The Global Gout Market Size Was Estimated at USD 2.75 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 10.38% from 2025 to 2035
• The Worldwide Gout Market Size is Expected to Reach USD 8.15 Billion by 2035
• Europe is expected to Grow the fastest during the forecast period.

According to a Research Report Published by Decisions Advisors and Consulting, The Global Gout Market Size was worth around USD 2.75 Billion in 2024 and is predicted to Grow to around USD 8.15 Billion by 2035 with a compound annual growth rate (CAGR) of 10.38% from 2025 to 2035. The market is driven by the growing popularity of the arthroscopic method of treating the condition because it makes it simple to remove uric acid deposits from patients' joints, improving functional outcomes. Additionally, the industry is expanding due to the creation of novel treatments and targeted therapies.

 

Market Overview

The gout market refers to the global healthcare industry segment focused on the diagnosis, treatment, and management of gout, a chronic inflammatory arthritis caused by elevated uric acid levels. Gout is a kind of arthritis where uric acid crystals accumulate in the joints, resulting in pain, oedema, and inflammation. The body naturally produces uric acid as it breaks down purines, which are present in a variety of foods and drinks. Gout can be very painful and usually happens suddenly. The big toe is the most frequently affected joint, but it can also affect the knee, ankle, wrist, and fingers. Patients having this illness may have severe joint pain, inflammation, redness, persistent discomfort, restricted range of motion, etc. Urate crystals in joints can be seen by the medical professional using a dual-energy computed tomography examination that combines multiple X-ray pictures. Joint fluid tests, blood workups, ultrasounds, and many other tests are performed to diagnose this illness.

 

Arthrosi Therapeutics, incubated by Viva Biotech, signed an acquisition agreement with Swedish Orphan Biovitrum AB (Sobi) valued at up to US $1.5 billion. The deal includes a large upfront payment and contingent milestones, and it is expected to close in the first half of 2026. This acquisition is a major milestone for Viva Biotech’s incubation strategy and a strategic bet by Sobi to dominate the gout treatment space.

 

Crystalys Therapeutics has officially launched with a massive $205 million Series A financing to advance its next-generation gout treatment, dotinurad, into global Phase 3 trials. Co-organised by several prominent life sciences investors, the funding was one of the biggest biotech launches of the year and gave the business the means to advance its primary program into clinical development.

 

Report Coverage

This research report categorises the gout market based on various segments and regions, forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the gout market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the gout market.     

 

Driving Factors  

The market for gout is driven by the rising incidence of metabolic syndrome, which raises uric acid levels. Furthermore, the market is expanding due to the increased prevalence of certain related risk factors, such as being overweight, having a family history of gout, eating a diet high in purines, certain medical diseases, etc. Another important growth-inducing aspect is the increasing use of colchicine and nonsteroidal anti-inflammatory medications to effectively decrease pain, regulate gout flares, and prevent future attacks in patients. Further, the market is benefiting from the growing use of uricosurics, such as probenecid, to treat a moderate-to-severe illness state by enhancing the kidneys' capacity to eliminate uric acid from the body. The gout market is driven by the growing popularity of arthroscopic treatment, which can eliminate uric acid from the joints, improving patients' functional outcomes.

 

Restraining Factors  

Despite the rising incidence of gout and developments in new treatments. Patient access is restricted, particularly in emerging nations, by high treatment prices and difficulties with payment, delayed diagnosis, under-treatment, and low awareness among patients and healthcare providers, as well as safety issues and side effects related to current medications. Competition from established therapies and generics puts pressure on new entrants' prices, which slowed down the market expansion.

 

Market Segmentation    

The gout market share is classified into treatment and application.    

• The urate-lowering agents segment accounted for the largest share in 2024 and is projected to grow at a significant CAGR over the forecast period.        

Based on the treatment, the gout market is segmented into NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others. Among these, the urate-lowering agents segment accounted for the largest share in 2024 and is projected to grow at a significant CAGR over the forecast period. Urate-decreasing agents are essential for the long-term treatment of gout since they actively lower uric acid levels to stop further episodes in addition to relieving symptoms. Drugs such as febuxostat and allopurinol have been essential in treatment recommendations, demonstrating their market dominance.

       

• The acute gout segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.     

Based on the application, the gout market is divided into acute gout and chronic gout. Among these, the acute gout segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The rapid instances of severe pain, oedema, and inflammation mostly affect the big toe and other joints. This is due to its higher incidence rate and urgent need for treatment.

 

Regional Segment Analysis of the Gout Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

Asia Pacific is projected to hold the largest share of the gout market over the predicted timeframe.     

Asia Pacific is anticipated to hold the largest share of the gout market over the predicted timeframe. Asia-Pacific is becoming the most popular region for outsourcing manufacturing services due to the availability of technical expertise, lower labour costs, and government backing for R&D investment to speed up new product development. This is caused by a number of causes, including the growing number of gout patients, the development of healthcare infrastructure, and the increased investment made by large players with local producers. For example, the Australian Bureau of Statistics estimates that 4.5% of Australians had gout in 2018. Males are more likely than females to get gout; about 8 out of 10 (79%) gout sufferers are men.

 

Europe is anticipated to grow at a rapid CAGR in the gout market during the forecast period. This is due to the availability of sophisticated diagnosis and treatment facilities, the growing number of elderly people who are susceptible to gout is increasing demand for effective treatment and therapies, and rising healthcare costs. The Italian gout market is predicted to grow at the quickest rate in the European region, followed by the UK gout market, due to rising healthcare spending, which also boosts business activity and government initiatives in creating effective gout diagnosis, treatment, and therapies. The growth of the gout market is expected to be positively impacted by these reasons. The presence of government organisations, as well as better government initiatives and healthcare frameworks, is also contributing to the expansion of the gout market in Europe.

 

Competitive Analysis:   

The report offers the appropriate analysis of the key organizations/companies involved within the gout market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

 

List of Key Companies

• Arrowhead Pharmaceuticals, Inc.
• AstraZeneca
• GSK plc.
• Hikma Pharmaceuticals plc
• Horizon Therapeutics plc
• Iroko Pharmaceutical LLC
• MERCK & Co. Inc.
• Mylan N.V.
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Teijin Pharma Limited
• Teva Pharmaceutical Industries Ltd.
• Zydus Group
• Others  

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

 

Recent Development

• In October 2025, at ACR Convergence 2025, several Phase III trials unveiled promising new gout therapies, most notably firsekibart for acute gouty arthritis and pozdeutinurad (AR882) for urate-lowering therapy. These advances target patients with limited treatment options, uncontrolled disease, or renal impairment, marking a significant step toward safer and more effective management of gout.

 

• In July 2025, Shanton Pharma’s investigational therapy SAP-001 received FDA Fast Track designation for the treatment of refractory gout. They are targeting patients with hyperuricemia who are unresponsive or intolerant to conventional urate-lowering therapies.

 

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors and Consulting has segmented the gout market based on the below-mentioned segments:

 

Global Gout Market, By Treatment

• NSAIDs
• Corticosteroids
• Colchicine
• Urate-Lowering Agents
• Others

 

Global Gout Market, By Application

• Acute Gout
• Chronic Gout

 

Global Gout Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

1. What is the projected size and growth rate of the global gout market?

The global gout market was valued at USD 2.75 billion in 2024 and is expected to reach USD 8.15 billion by 2035, growing at a CAGR of 10.38% from 2025 to 2035.

 

2. What are the main market segments by treatment and application?

By treatment: NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents (the largest share in 2024), and Others. By application: Acute Gout (highest revenue in 2024) and Chronic Gout.

 

3. Which region holds the largest market share, and which is growing fastest?

Asia-Pacific is projected to hold the largest share due to rising gout cases, healthcare infrastructure growth, and manufacturing outsourcing. Europe is expected to grow at the fastest CAGR, driven by advanced diagnostics, ageing populations, and healthcare spending in countries like Italy and the UK.

 

4. What are the primary drivers of gout market growth?

Key drivers include rising metabolic syndrome and risk factors (e.g., obesity, high-purine diets), increased use of colchicine, NSAIDs, and uricosurics like probenecid, and the popularity of arthroscopic treatments for uric acid removal. Novel therapies and targeted drugs also fuel expansion.

 

5. What challenges or restraining factors affect the market?

High treatment costs, limited access in emerging markets, delayed diagnosis, low awareness, side effects of medications, and competition from generics hinder growth.

 

6. Who are the key players in the gout market?

Major companies include Arrowhead Pharmaceuticals, AstraZeneca, GSK plc., Hikma Pharmaceuticals, Horizon Therapeutics, Iroko Pharmaceuticals, Merck & Co., Mylan N.V., Novartis AG, Takeda, Teijin Pharma, Teva, Zydus Group, and others.

 

7. Who is the target audience for this market report?

Market players, investors, end-users, government authorities, consulting firms, venture capitalists, and value-added resellers.